Calidi Biotherapeutics Stock Net Income
| CLDI Stock | 1.02 0.02 1.92% |
As of the 24th of January, Calidi Biotherapeutics shows the Standard Deviation of 3.9, risk adjusted performance of (0.11), and Mean Deviation of 2.86. Calidi Biotherapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Calidi Biotherapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Calidi Biotherapeutics' valuation are provided below:We have found one hundred twenty available fundamental signals for Calidi Biotherapeutics, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of Calidi Biotherapeutics prevailing fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 26.5 M. Enterprise Value is estimated to decrease to about 32.1 M This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -20 M | -21 M | |
| Net Loss | -22.9 M | -24 M | |
| Net Loss | -20 M | -21 M | |
| Net Loss | (38.33) | (40.24) | |
| Net Income Per E B T | 0.90 | 0.94 |
Calidi | Net Income | Build AI portfolio with Calidi Stock |
Latest Calidi Biotherapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Calidi Biotherapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Calidi Biotherapeutics financial statement analysis. It represents the amount of money remaining after all of Calidi Biotherapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Calidi Biotherapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Calidi Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (22.21 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Calidi Net Income Regression Statistics
| Arithmetic Mean | (12,698,814) | |
| Coefficient Of Variation | (58.95) | |
| Mean Deviation | 6,370,090 | |
| Median | (7,937,000) | |
| Standard Deviation | 7,485,411 | |
| Sample Variance | 56T | |
| Range | 21.3M | |
| R-Value | (0.76) | |
| Mean Square Error | 25.4T | |
| R-Squared | 0.57 | |
| Significance | 0.0004 | |
| Slope | (1,123,593) | |
| Total Sum of Squares | 896.5T |
Calidi Net Income History
Other Fundumenentals of Calidi Biotherapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Calidi Biotherapeutics Net Income component correlations
Calidi Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Calidi Biotherapeutics is extremely important. It helps to project a fair market value of Calidi Stock properly, considering its historical fundamentals such as Net Income. Since Calidi Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Calidi Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Calidi Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Calidi Biotherapeutics. If investors know Calidi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Calidi Biotherapeutics is measured differently than its book value, which is the value of Calidi that is recorded on the company's balance sheet. Investors also form their own opinion of Calidi Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Calidi Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Calidi Biotherapeutics' market value can be influenced by many factors that don't directly affect Calidi Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Calidi Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Calidi Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Calidi Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Calidi Biotherapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Calidi Biotherapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Calidi Biotherapeutics.
| 10/26/2025 |
| 01/24/2026 |
If you would invest 0.00 in Calidi Biotherapeutics on October 26, 2025 and sell it all today you would earn a total of 0.00 from holding Calidi Biotherapeutics or generate 0.0% return on investment in Calidi Biotherapeutics over 90 days. Calidi Biotherapeutics is related to or competes with Clearmind Medicine, Can Fite, Kazia Therapeutics, Silo Pharma, CNS Pharmaceuticals, 60 Degrees, and Xenetic Biosciences. Calidi Biotherapeutics is entity of United States More
Calidi Biotherapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Calidi Biotherapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Calidi Biotherapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.17) | |||
| Maximum Drawdown | 24.52 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 5.56 |
Calidi Biotherapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Calidi Biotherapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Calidi Biotherapeutics' standard deviation. In reality, there are many statistical measures that can use Calidi Biotherapeutics historical prices to predict the future Calidi Biotherapeutics' volatility.| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (0.65) | |||
| Total Risk Alpha | (0.98) | |||
| Treynor Ratio | (1.06) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Calidi Biotherapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Calidi Biotherapeutics January 24, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (1.05) | |||
| Mean Deviation | 2.86 | |||
| Coefficient Of Variation | (646.02) | |||
| Standard Deviation | 3.9 | |||
| Variance | 15.22 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (0.65) | |||
| Total Risk Alpha | (0.98) | |||
| Treynor Ratio | (1.06) | |||
| Maximum Drawdown | 24.52 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 5.56 | |||
| Skewness | (0.19) | |||
| Kurtosis | 1.77 |
Calidi Biotherapeutics Backtested Returns
Calidi Biotherapeutics secures Sharpe Ratio (or Efficiency) of -0.16, which signifies that the company had a -0.16 % return per unit of risk over the last 3 months. Calidi Biotherapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Calidi Biotherapeutics' Mean Deviation of 2.86, standard deviation of 3.9, and Risk Adjusted Performance of (0.11) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.58, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Calidi Biotherapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Calidi Biotherapeutics is expected to be smaller as well. At this point, Calidi Biotherapeutics has a negative expected return of -0.61%. Please make sure to confirm Calidi Biotherapeutics' total risk alpha, accumulation distribution, period momentum indicator, as well as the relationship between the potential upside and day median price , to decide if Calidi Biotherapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.36 |
Below average predictability
Calidi Biotherapeutics has below average predictability. Overlapping area represents the amount of predictability between Calidi Biotherapeutics time series from 26th of October 2025 to 10th of December 2025 and 10th of December 2025 to 24th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Calidi Biotherapeutics price movement. The serial correlation of 0.36 indicates that just about 36.0% of current Calidi Biotherapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.36 | |
| Spearman Rank Test | 0.28 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Calidi Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Calidi Biotherapeutics reported net income of (22.21 Million). This is 106.51% lower than that of the Biotechnology sector and 131.71% lower than that of the Health Care industry. The net income for all United States stocks is 103.89% higher than that of the company.
Calidi Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Calidi Biotherapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Calidi Biotherapeutics could also be used in its relative valuation, which is a method of valuing Calidi Biotherapeutics by comparing valuation metrics of similar companies.Calidi Biotherapeutics is currently under evaluation in net income category among its peers.
Calidi Fundamentals
| Return On Asset | -1.2 | ||||
| Current Valuation | 387.43 K | ||||
| Shares Outstanding | 7.17 M | ||||
| Shares Owned By Insiders | 15.39 % | ||||
| Shares Owned By Institutions | 3.26 % | ||||
| Number Of Shares Shorted | 154.54 K | ||||
| Price To Book | 1.08 X | ||||
| Price To Sales | 50.83 X | ||||
| Gross Profit | 31 K | ||||
| EBITDA | (19.73 M) | ||||
| Net Income | (22.21 M) | ||||
| Total Debt | 7.04 M | ||||
| Book Value Per Share | 0.98 X | ||||
| Cash Flow From Operations | (19.69 M) | ||||
| Short Ratio | 2.01 X | ||||
| Earnings Per Share | 0.36 X | ||||
| Target Price | 120.0 | ||||
| Number Of Employees | 28 | ||||
| Beta | 1.09 | ||||
| Market Capitalization | 7.31 M | ||||
| Total Asset | 14.18 M | ||||
| Retained Earnings | (121.72 M) | ||||
| Working Capital | 731 K | ||||
| Net Asset | 14.18 M |
About Calidi Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Calidi Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Calidi Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Calidi Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Calidi Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Calidi Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Calidi Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Calidi Biotherapeutics Stock:Check out Calidi Biotherapeutics Piotroski F Score and Calidi Biotherapeutics Altman Z Score analysis. For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Calidi Biotherapeutics. If investors know Calidi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Calidi Biotherapeutics is measured differently than its book value, which is the value of Calidi that is recorded on the company's balance sheet. Investors also form their own opinion of Calidi Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Calidi Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Calidi Biotherapeutics' market value can be influenced by many factors that don't directly affect Calidi Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Calidi Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Calidi Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Calidi Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.